Genetic polymorphism of N-acetyltransferases, glutathione S-transferase M1 and NAD(P)H: quinone oxidoreductase in relation to malignant and benign pancreatic disease risk

H. Bartsch, C. Malaveille, A. B. Lowenfels, P. Maisonneuve, A. Hautefeuille, P. Boyle, P. Banks, G. Cavallini, L. Domellöf, L. Gullo, E. Krag, P. G. Lankisch, C. S. Pitchumoni, A. L. Warshaw

Research output: Contribution to journalArticle

Abstract

Carcinogens present in cigarette smoke and diet have been associated with pancreatic cancer. We hypothesized that heterocyclic and aromatic amines implicated in these exposures could be involved as causative agents and that therefore genetic variation in enzymes metabolizing these carcinogens could modify the risk of developing malignant and benign pancreatic disease. The effect of the genetic polymorphism of acetyl-transferases (NAT1 and NAT2), glutathione S-transferase M1 (GSTM1) and NAD(P)H: quinone oxidoreductase 1 (NQO1) on the risk of pancreatic diseases (cancer, pancreatitis) was examined in a case-control study. PCR-based assays were used for genotype analysis of genomic DNA from whole blood cells. Samples collected from Caucasian patients with diagnosed pancreatic cancer (n = 81), with non-alcoholic (n = 41) and alcoholic pancreatitis (n = 73) and from asymptomatic control subjects (n = 78) were analysed. The prevalence of GSTM1 null genotype and of NAT2 fast and slow acetylator genotypes and the distribution of frequencies for NQO1 genotypes did not differ in subjects with pancreatic diseases vs controls. For NAT1 slow acetylators a non-significant excess (P = 0.18) was found among pancreatic cancer cases vs controls. There was a significant over- representation of the GSTM1 AB or B genotype in all pancreatic disease cases combined (OR = 2.6; P <0.05). When concurrent controls were pooled with literature controls (n = 1427), OR was 1.4 (P = 0.08). The results of this study, requiring confirmation, suggest that the polymorphism of GSTM1 and NAT1 enzymes may be associated with a modest increase in susceptibility to pancreatic disease.

Original languageEnglish
Pages (from-to)215-223
Number of pages9
JournalEuropean Journal of Cancer Prevention
Volume7
Issue number3
DOIs
Publication statusPublished - 1998

Fingerprint

Pancreatic Diseases
Acetyltransferases
Genetic Polymorphisms
NAD
Oxidoreductases
Pancreatic Neoplasms
Genotype
Carcinogens
Alcoholic Pancreatitis
Enzymes
Transferases
Glutathione Transferase
Smoke
Tobacco Products
Pancreatitis
Amines
Case-Control Studies
Blood Cells
benzoquinone
glutathione S-transferase M1

Keywords

  • Alcoholic pancreatitis
  • Asymptomatic Caucasian subjects
  • Diet
  • Genetic polymorphism
  • Glutathione
  • heterocyclic/aromatic amines
  • N-acetyl-transferase
  • NAD(P)H:quinone oxidoreductase
  • Pancreatic cancer
  • S-transferase M1

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Genetic polymorphism of N-acetyltransferases, glutathione S-transferase M1 and NAD(P)H : quinone oxidoreductase in relation to malignant and benign pancreatic disease risk. / Bartsch, H.; Malaveille, C.; Lowenfels, A. B.; Maisonneuve, P.; Hautefeuille, A.; Boyle, P.; Banks, P.; Cavallini, G.; Domellöf, L.; Gullo, L.; Krag, E.; Lankisch, P. G.; Pitchumoni, C. S.; Warshaw, A. L.

In: European Journal of Cancer Prevention, Vol. 7, No. 3, 1998, p. 215-223.

Research output: Contribution to journalArticle

Bartsch, H, Malaveille, C, Lowenfels, AB, Maisonneuve, P, Hautefeuille, A, Boyle, P, Banks, P, Cavallini, G, Domellöf, L, Gullo, L, Krag, E, Lankisch, PG, Pitchumoni, CS & Warshaw, AL 1998, 'Genetic polymorphism of N-acetyltransferases, glutathione S-transferase M1 and NAD(P)H: quinone oxidoreductase in relation to malignant and benign pancreatic disease risk', European Journal of Cancer Prevention, vol. 7, no. 3, pp. 215-223. https://doi.org/10.1097/00008469-199806000-00006
Bartsch, H. ; Malaveille, C. ; Lowenfels, A. B. ; Maisonneuve, P. ; Hautefeuille, A. ; Boyle, P. ; Banks, P. ; Cavallini, G. ; Domellöf, L. ; Gullo, L. ; Krag, E. ; Lankisch, P. G. ; Pitchumoni, C. S. ; Warshaw, A. L. / Genetic polymorphism of N-acetyltransferases, glutathione S-transferase M1 and NAD(P)H : quinone oxidoreductase in relation to malignant and benign pancreatic disease risk. In: European Journal of Cancer Prevention. 1998 ; Vol. 7, No. 3. pp. 215-223.
@article{be6e7a29b6414f43b1be193ea2d49033,
title = "Genetic polymorphism of N-acetyltransferases, glutathione S-transferase M1 and NAD(P)H: quinone oxidoreductase in relation to malignant and benign pancreatic disease risk",
abstract = "Carcinogens present in cigarette smoke and diet have been associated with pancreatic cancer. We hypothesized that heterocyclic and aromatic amines implicated in these exposures could be involved as causative agents and that therefore genetic variation in enzymes metabolizing these carcinogens could modify the risk of developing malignant and benign pancreatic disease. The effect of the genetic polymorphism of acetyl-transferases (NAT1 and NAT2), glutathione S-transferase M1 (GSTM1) and NAD(P)H: quinone oxidoreductase 1 (NQO1) on the risk of pancreatic diseases (cancer, pancreatitis) was examined in a case-control study. PCR-based assays were used for genotype analysis of genomic DNA from whole blood cells. Samples collected from Caucasian patients with diagnosed pancreatic cancer (n = 81), with non-alcoholic (n = 41) and alcoholic pancreatitis (n = 73) and from asymptomatic control subjects (n = 78) were analysed. The prevalence of GSTM1 null genotype and of NAT2 fast and slow acetylator genotypes and the distribution of frequencies for NQO1 genotypes did not differ in subjects with pancreatic diseases vs controls. For NAT1 slow acetylators a non-significant excess (P = 0.18) was found among pancreatic cancer cases vs controls. There was a significant over- representation of the GSTM1 AB or B genotype in all pancreatic disease cases combined (OR = 2.6; P <0.05). When concurrent controls were pooled with literature controls (n = 1427), OR was 1.4 (P = 0.08). The results of this study, requiring confirmation, suggest that the polymorphism of GSTM1 and NAT1 enzymes may be associated with a modest increase in susceptibility to pancreatic disease.",
keywords = "Alcoholic pancreatitis, Asymptomatic Caucasian subjects, Diet, Genetic polymorphism, Glutathione, heterocyclic/aromatic amines, N-acetyl-transferase, NAD(P)H:quinone oxidoreductase, Pancreatic cancer, S-transferase M1",
author = "H. Bartsch and C. Malaveille and Lowenfels, {A. B.} and P. Maisonneuve and A. Hautefeuille and P. Boyle and P. Banks and G. Cavallini and L. Domell{\"o}f and L. Gullo and E. Krag and Lankisch, {P. G.} and Pitchumoni, {C. S.} and Warshaw, {A. L.}",
year = "1998",
doi = "10.1097/00008469-199806000-00006",
language = "English",
volume = "7",
pages = "215--223",
journal = "European Journal of Cancer Prevention",
issn = "0959-8278",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Genetic polymorphism of N-acetyltransferases, glutathione S-transferase M1 and NAD(P)H

T2 - quinone oxidoreductase in relation to malignant and benign pancreatic disease risk

AU - Bartsch, H.

AU - Malaveille, C.

AU - Lowenfels, A. B.

AU - Maisonneuve, P.

AU - Hautefeuille, A.

AU - Boyle, P.

AU - Banks, P.

AU - Cavallini, G.

AU - Domellöf, L.

AU - Gullo, L.

AU - Krag, E.

AU - Lankisch, P. G.

AU - Pitchumoni, C. S.

AU - Warshaw, A. L.

PY - 1998

Y1 - 1998

N2 - Carcinogens present in cigarette smoke and diet have been associated with pancreatic cancer. We hypothesized that heterocyclic and aromatic amines implicated in these exposures could be involved as causative agents and that therefore genetic variation in enzymes metabolizing these carcinogens could modify the risk of developing malignant and benign pancreatic disease. The effect of the genetic polymorphism of acetyl-transferases (NAT1 and NAT2), glutathione S-transferase M1 (GSTM1) and NAD(P)H: quinone oxidoreductase 1 (NQO1) on the risk of pancreatic diseases (cancer, pancreatitis) was examined in a case-control study. PCR-based assays were used for genotype analysis of genomic DNA from whole blood cells. Samples collected from Caucasian patients with diagnosed pancreatic cancer (n = 81), with non-alcoholic (n = 41) and alcoholic pancreatitis (n = 73) and from asymptomatic control subjects (n = 78) were analysed. The prevalence of GSTM1 null genotype and of NAT2 fast and slow acetylator genotypes and the distribution of frequencies for NQO1 genotypes did not differ in subjects with pancreatic diseases vs controls. For NAT1 slow acetylators a non-significant excess (P = 0.18) was found among pancreatic cancer cases vs controls. There was a significant over- representation of the GSTM1 AB or B genotype in all pancreatic disease cases combined (OR = 2.6; P <0.05). When concurrent controls were pooled with literature controls (n = 1427), OR was 1.4 (P = 0.08). The results of this study, requiring confirmation, suggest that the polymorphism of GSTM1 and NAT1 enzymes may be associated with a modest increase in susceptibility to pancreatic disease.

AB - Carcinogens present in cigarette smoke and diet have been associated with pancreatic cancer. We hypothesized that heterocyclic and aromatic amines implicated in these exposures could be involved as causative agents and that therefore genetic variation in enzymes metabolizing these carcinogens could modify the risk of developing malignant and benign pancreatic disease. The effect of the genetic polymorphism of acetyl-transferases (NAT1 and NAT2), glutathione S-transferase M1 (GSTM1) and NAD(P)H: quinone oxidoreductase 1 (NQO1) on the risk of pancreatic diseases (cancer, pancreatitis) was examined in a case-control study. PCR-based assays were used for genotype analysis of genomic DNA from whole blood cells. Samples collected from Caucasian patients with diagnosed pancreatic cancer (n = 81), with non-alcoholic (n = 41) and alcoholic pancreatitis (n = 73) and from asymptomatic control subjects (n = 78) were analysed. The prevalence of GSTM1 null genotype and of NAT2 fast and slow acetylator genotypes and the distribution of frequencies for NQO1 genotypes did not differ in subjects with pancreatic diseases vs controls. For NAT1 slow acetylators a non-significant excess (P = 0.18) was found among pancreatic cancer cases vs controls. There was a significant over- representation of the GSTM1 AB or B genotype in all pancreatic disease cases combined (OR = 2.6; P <0.05). When concurrent controls were pooled with literature controls (n = 1427), OR was 1.4 (P = 0.08). The results of this study, requiring confirmation, suggest that the polymorphism of GSTM1 and NAT1 enzymes may be associated with a modest increase in susceptibility to pancreatic disease.

KW - Alcoholic pancreatitis

KW - Asymptomatic Caucasian subjects

KW - Diet

KW - Genetic polymorphism

KW - Glutathione

KW - heterocyclic/aromatic amines

KW - N-acetyl-transferase

KW - NAD(P)H:quinone oxidoreductase

KW - Pancreatic cancer

KW - S-transferase M1

UR - http://www.scopus.com/inward/record.url?scp=15644376139&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=15644376139&partnerID=8YFLogxK

U2 - 10.1097/00008469-199806000-00006

DO - 10.1097/00008469-199806000-00006

M3 - Article

C2 - 9696930

AN - SCOPUS:15644376139

VL - 7

SP - 215

EP - 223

JO - European Journal of Cancer Prevention

JF - European Journal of Cancer Prevention

SN - 0959-8278

IS - 3

ER -